^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Fallopian Tube Cancer |
| Drug: | navixizumab (OMP-305B83) (VEGFR inhibitor, DLL4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
Published date:
10/07/2019
Excerpt:
Mereo BioPharma...announces that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to navicixizumab for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least 3 prior therapies and/or prior bevacizumab.
